Conclusion of non-exclusive discount contracts in accordance with Section 130a (8) SGB V for drugs with the active ingredient tocilizumab (L04AC07) within the period from November 1, 2020 to October 31, 2022 with the option of concluding a contract at any time (open-house model).

The AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse offers all interested pharmaceutical companies without a selection decision discount contracts with the active ingredient tocilizumab (L04AC07). Contracts are concluded as part of an “open house model”. The contracts offered are not exclusive; Contracts with all market participants (pharmaceutical companies) are desired by the AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse. In the open house model, uniform conditions apply to all participants. The content of the contract, terms and conditions and access procedures are uniform - individual negotiations are not conducted.

The contract periods are a maximum of 24 months, the earliest contract start is November 1st, 2020. All contracts end no later than 24 months after the date of the earliest commencement of the contract, regardless of the date of the respective conclusion of the contract. Joining or entering into a contract can take place within the 24-month period on the first of each month.

There is a right of termination 6 weeks at the end of each month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents.

The AOK Rhineland-Palatinate / Saarland - The health insurance company reserves the right to replace the non-exclusive open house discount contracts with exclusive discount contracts as part of the Europe-wide tender process during the contract period. With the entry into force of exclusive discount contracts, the open house contracts are terminated in accordance with the contractual regulation, ie the open house contracts end automatically.

Interested pharmaceutical companies can request the participation documents and the contract documents from the contact address given under I.1). Contracts for the active ingredient tocilizumab (L04AC07) will be concluded for the first time with effect from November 1, 2020. Interested parties who would like to become a contractual partner on this date must submit the contract documents to the AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse by September 30, 2020. It depends on the access at the AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse.

Note: The first award in this procedure will be granted no earlier than 10 calendar days after the publication of this EU announcement in the Official Journal. Later contracts can be concluded for the first of a month during the 24-month maximum term. For interested parties who would like to become contractual partners on these follow-up dates, the receipt of the contract documents including Appendix 1 must be submitted no later than the end of the month preceding the previous month of the desired start of the contract (e.g. receipt April 30th when the contract starts June 1st). The exact entry deadlines will be announced with the contract documents. This publication is not a public contract within the meaning of the procurement coordination directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.